ALTERITY THERAPEUTICS LTD

Over the past 90 days, Alterity Therapeutics has reported no cyber incidents, bankruptcy risks, restatements, or officer departures—a clean compliance record during our observation window. However, absence of recent red flags does not indicate overall risk profile; the company operates in the capital-intensive biotech sector where equity dilution and financing cycles merit deeper examination. The full $49 Report extends analysis to 12 months of SEC filings, calculates dilution risk scores based on share issuance patterns, maps the complete financing history, and flags AI-detected risk signals that don't surface in standard compliance reviews. The full $49 Report adds dilution trajectory analysis, 12-month 8-K context, capital structure stress testing, and sector-specific financing risk scoring.